Τα εμβόλια για τον COVID-19 που αναπτύσσονται από τις Moderna, Pfizer, AstraZeneca και άλλες εταιρείες, και βρίσκονται επί του παρόντος σε κλινικές δοκιμές Φάσης III, μπορεί να μην καλύπτουν τόσο καλά ανθρώπους γενετικής κατtreatmentς της Μαύρης, της Ασιατικής φυλής αλλά λευκούς, σύμφωνα με μια study published by the Massachusetts Institute of Technology.
The study published on Thursday in the scientific journal Cell Systems.
"There are obviously many factors to consider, but our preliminary results suggest that on average, people of Black or Asian race could have a slightly increased risk of vaccine ineffectiveness," says one of the study's authors. David K. who is at MIT's Computer Science and Artificial Intelligence Laboratory (CSAIL from the Computer Science and Artificial Intelligence Laboratory).
His statement is included in the press release issued by MIT.
The report, entitled "Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and their Augmentation by Compact Peptide Sets," originally published (PDF) on the Bioarxiv pre-print server.
Enthusiasm has grown in recent weeks as Moderna, Pfizer and AstraZeneca announced all the initial results from the Phase III tests and showed surprisingly strong immunity rates (94% to 95%).
But according to the MIT study, many of the vaccines, including Moderna and Pfizer and AstraZeneca, have the same weakness, that is, they do not use different sets of viral particles to stimulate the same level of immune response in all humans, depending on the genetic background.
Η έκθεση βασίζεται σε μοντέλα υπολογιστών silico. Ο Gifford και οι συν-συγγραφείς Ge Liu και Brandon Carter, two doctoral students with MIT's CSAIL, used machine learning models to predict, based on patient data and models of proteins in the immune system, how likely vaccines would be to succeed. That is, to successfully stimulate an immune response in different population groups based on self-reported ethnicity or genetic ancestry.
Also, engineering learning of MIT designed a COVID-19 vaccine that could cover many more people.
The study is based on work done this summer by the team to develop two computer models that provide vaccine coverage. One, called OptiVax, predicts the stimulation of immune responses to a vaccine, and the second, called EvalVax, maps the immune response to the biochemistry of population groups based on ethnic or genetic origin.